[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658395":3},{"organization":4,"outcomesModule":7,"designInfo":43,"detailedDescription":11,"studyPopulation":11,"armGroups":53,"interventions":63,"overallOfficials":74,"centralContacts":77,"locations":11,"responsibleParty":85,"collaborators":11,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":11,"eligibilityCriteria":93,"healthyVolunteers":94,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":112,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":11},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":11},[9,13,15,17,19,21,23],{"measure":10,"description":11,"timeFrame":12},"Maximum observed plasma concentration (Cmax)",null,"Up to Day 85",{"measure":14,"description":11,"timeFrame":12},"Time of maximum observed plasma concentration (Tmax)",{"measure":16,"description":11,"timeFrame":12},"Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]",{"measure":18,"description":11,"timeFrame":12},"Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]",{"measure":20,"description":11,"timeFrame":12},"Total body clearance in intravenous infusion (CLT)",{"measure":22,"description":11,"timeFrame":12},"Volume of distribution of terminal phase in intravenous administration (Vz)",{"measure":24,"description":11,"timeFrame":12},"Apparent terminal serum half-life [T-HALF]",[26,28,31,33,35,37,39,41],{"measure":27,"description":11,"timeFrame":12},"Number of participants with anti-drug antibody (ADA) formation",{"measure":29,"description":11,"timeFrame":30},"Number of participants with adverse events (AEs)","Up to approximately 85 days",{"measure":32,"description":11,"timeFrame":30},"Number of participants with vital sign abnormalities",{"measure":34,"description":11,"timeFrame":30},"Number of participants with 12-lead electrocardiogram (12-lead-ECG) abnormalities",{"measure":36,"description":11,"timeFrame":30},"Number of participants with physical examination abnormalities",{"measure":38,"description":11,"timeFrame":30},"Number of participants with body weight abnormalities",{"measure":40,"description":11,"timeFrame":30},"Number of participants with clinical laboratory abnormalities",{"measure":42,"description":11,"timeFrame":30},"Number of Participants with Treatment Emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)",{"allocation":44,"interventionModel":45,"interventionModelDescription":11,"primaryPurpose":46,"observationalModel":11,"timePerspective":11,"maskingInfo":47},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":48,"maskingDescription":11,"whoMasked":49},"TRIPLE",[50,51,52],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[54,59],{"label":55,"type":56,"description":11,"interventionNames":57},"BMS-986446","EXPERIMENTAL",[58],"Drug: BMS-986446",{"label":60,"type":56,"description":11,"interventionNames":61},"Placebo",[62],"Other: Placebo",[64,71],{"type":65,"name":55,"description":66,"armGroupLabels":67,"otherNames":68},"DRUG","Specified dose on specified days",[55],[69,70],"PRX005","Moponetug",{"type":72,"name":60,"description":66,"armGroupLabels":73,"otherNames":11},"OTHER",[60],[75],{"name":5,"affiliation":5,"role":76},"STUDY_DIRECTOR",[78,83],{"name":79,"role":80,"phone":81,"phoneExt":11,"email":82},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":84,"role":80,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",{"type":86,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658395","phase-1-study-to-assess-drug-levels-immune-response-safety-and-tolerability-of-bms-986446-in-healthy-chinese-participants-100658395",false,"NCT07852962","Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.","A Phase 1, Double-blind, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of BMS-986446 Following Intravenous Administration in Healthy Chinese Participants","Inclusion Criteria:\n\n* Participants must be of Chinese ethnicity (both biological parents are ethnically Chinese).\n* Participants must be Healthy adult male and female (as assigned at birth and non-pregnant and non-nursing).\n* Participants must have BMI of 18.0 to 28.0 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Participants must not have general history of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated, or hematological disorder; allergic disease; metabolic disorder; cancer; or cirrhosis.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","65 Years",{"count":99,"type":100},10,"ESTIMATED","INTERVENTIONAL",[103],"PHASE1","The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.",[106],"Healthy Volunteers",[108,109,55,110,111],"Pharmacokinetics","PK","Healthy Chinese Participants","IV administration","NOT_YET_RECRUITING","2026-09-24",{"date":115,"type":116},"2026-10-01","ACTUAL",{"date":118,"type":100},"2027-02-10",{"date":120,"type":100},"2027-07-18",{"name":5,"class":6}]